Autoantibody idiotype on B-cell receptor (BCR idiotype)

Autoantibody idiotypes on B-cell receptors (BCRs) are the unique molecular structures within the variable regions of receptors found on the surface of autoreactive B cells (Ellebrecht et al., 2016, Science). These idiotypes define the specificity of the B cell for a particular self-antigen, making them the primary drivers of autoantibody production in autoimmune diseases (Parvathaneni et al., 2022, Front Immunol). Targeting these idiotypes represents a precision medicine approach, aiming to selectively eliminate pathogenic B-cell clones while sparing the broader B-cell population necessary for protective immunity. Therapeutic strategies include Chimeric Autoantibody Receptor (CAART) T-cell therapies, which utilize the autoantigen itself as the targeting domain to bind and kill B cells expressing the corresponding BCR idiotype (Cabaletta Bio, 2024). This mechanism is currently being investigated for the treatment of antibody-mediated diseases such as Pemphigus Vulgaris and Myasthenia Gravis, offering a potential alternative to broad immunosuppression (Oh et al., 2023, Nature Biomedical Engineering). By focusing on the idiotype, these therapies aim to achieve long-term remission by removing the source of autoantibodies. This approach contrasts with traditional therapies that target all B cells, such as anti-CD20 antibodies. The specificity of the idiotype-antigen interaction is the key to reducing off-target effects in these novel treatments.

Other names

B-cell receptor idiotypeAutoreactive B-cell receptorAntigen-specific B-cell receptorBCR variable regionIdiotypic determinant

Selective depletion of autoreactive B cells through antigen-specific binding to the B-cell receptor idiotype, leading to targeted cytotoxicity or neutralization.